Drug Profile
Research programme: cancer immunotherapeutics - Pfizer
Alternative Names: Anti-CD134 monoclonal antibody - Pfizer; Anti-macrophage colony stimulating factor antibody- Pfizer; anti-MCSF-antibody- Pfizer; Anti-OX40 monoclonal antibody - Pfizer; Anti-PD1 monoclonal antibody - Pfizer; CCR2-inhibitor- Pfizer; Prostate cancer vaccine - PfizerLatest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Pfizer
- Class Bispecific antibodies; Cancer vaccines; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; OX40 receptor antagonists; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Prostate cancer
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 22 Jun 2018 Alexo Therapeutics is now called ALX Oncology